After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

AstraZeneca has watched superstar SGLT2 diabetes med Farxiga nail trial after trial in highly coveted kidney and heart failure indications, with the FDA expediting reviews to back them up. The one ...

New data showed consistent effect of FARXIGA in patients with heart failure with reduced ejection fraction, regardless of background therapy WILMINGTON, Del.--(BUSINESS WIRE)-- New data from a ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular ...

AstraZeneca Plc’s playbook to break into the red-hot obesity market rests on improving upon existing medicines, offering ...

Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.--(BUSINESS WIRE)-- High-level results from the ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 ...

Dear Dr. Roach: My question is: What is the difference between prediabetes and diabetes, and which do I have? I am male, 85 years old, 170 pounds, and 6 feet and 1 inch tall. I was treated for heart ...

Farxiga can cost up to $600 without insurance, with costs varying by pharmacy and whether you choose the brand or the generic. With Medicare coverage, your out-of-pocket costs depend on your plan.

Farxiga (dapagliflozin) may not be safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you should ...

Astrazeneca plc followed up its win a year ago in heart failure (HF) with yet another approval for its oral SGLT2 inhibitor, Farxiga (dapagliflozin), now cleared by the FDA to reduce the odds of ...

Maryland’s Prescription Drug Affordability Board says it has identified two diabetes drugs that could be made more affordable for residents based on a cost study by the state agency. During a meeting ...